| No |
Date |
Delivery |
Topik |
Jurnal |
Referensi |
RP/Fasilitator |
| 1 |
___ |
Kuliah |
Introduction to Critical Appraisal |
___ |
___ |
___ |
| 2 |
___ |
Kuliah |
Interpretation of Research Results (CI, p-value, adjusted OR, Hazard Ratio, etc) |
___ |
___ |
___ |
| 3 |
___ |
Lab: Group Discussion |
Critical Appraisal and EBM of Case Control Studies |
___ |
___ |
___ |
| 4 |
___ |
Lab: Group Discussion |
Critical Appraisal and EBM of Cohort |
___ |
___ |
___ |
| ___ |
___ |
___ |
___ |
___ |
___ |
___ |
| ___ |
___ |
___ |
___ |
___ |
___ |
___ |
| ___ |
___ |
___ |
___ |
___ |
___ |
___ |
| ___ |
___ |
___ |
UTS |
___ |
___ |
___ |
| 5 |
___ |
Kuliah |
Screening |
___ |
___ |
___ |
| 6 |
___ |
Kuliah |
Diagnostic Testing |
___ |
___ |
___ |
| 7 |
___ |
Lab: Group Discussion |
Critical Appraisal and EBM: Diagnostic Study |
___ |
___ |
___ |
| 8 |
___ |
Kuliah |
Ethical Issue: Informed consent, correct information, ethical clearance |
___ |
___ |
Yulia Sofiatin |
| 9 |
___ |
Kuliah |
Critical Appraisal and EBM: Clinical Trial (Therapeutic Study) |
___ |
___ |
___ |
| ___ |
___ |
___ |
___ |
___ |
___ |
___ |
| ___ |
___ |
___ |
___ |
___ |
___ |
___ |
| ___ |
___ |
___ |
UAS |
___ |
___ |
___ |
